Platelet Function and Pharmacology of Antiplatelet Drugs

Nurden, Alan T.; Duperat, Véronique Guyonnet; Nurden, Paquita

doi:10.1159/000108274

Search citation statements

Order By: Relevance

Paper Sections

Select...

What Antiplatelet Agents Are Now Used?1

Why Secondary Prevention?1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2000

2015

Publication Types

Select...

Article4

Book3

Relationship

Self Cite0

Independent7

Authors

Journals

Cited by 9 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aspirin inhibits platelet aggregation and secretion by preventing the synthesis of prostaglandins and thromboxane A 2 . This action is achieved by inhibiting the cyclooxygenase enzyme that converts arachidonic acid to prostaglandin G 2 , the precursor of thromboxane A 2 [24]. Aspirin, however, also inhibits the production of prostacyclin by endothelial cells.…”

Section: What Antiplatelet Agents Are Now Used?mentioning

confidence: 99%

Antiplatelet Therapy in Stroke Prevention: Present and Future

Caplan¹

2006

Cerebrovasc Dis

View full text Add to dashboard Cite

White platelet-fibrin thrombi often form on roughened endothelial surfaces and unstable arterial plaques. Agents that reduce the tendency of platelets to aggregate, agglutinate, and secrete and to attach to endothelial surfaces have been explored as agents that prevent brain and heart infarction. Aspirin, ticlopidine, clopidogrel, dipyridamole, cilostazol, and glycoprotein llb/llla inhibitors are all used now and have various different modes of action and functions.

show abstract

Section: What Antiplatelet Agents Are Now Used?mentioning

confidence: 99%

Antiplatelet Therapy in Stroke Prevention: Present and Future

Caplan¹

2006

Cerebrovasc Dis

View full text Add to dashboard Cite

show abstract

“…Dipyridamole elevates cyclic adenosine monophosphate (cAMP), which results in vasodilation, platelet antiaggregation, and inhibition of thromboxane A2 [31]. Ticlopidine and clopidogrel inhibit platelet binding to fibrinogen and are selective inhibitors of the adenosine diphosphate (ADP) pathway of platelet aggregation [33].…”

Section: Why Secondary Prevention?mentioning

confidence: 99%